[DOI] [PubMed] [Google Scholar] 51.Fader AN, Arriba LN, Frasure HE, von Gruenigen VE
In addition to suppressing appetite, GLP-1 agonists block the action of glucagon, a hormone that signals the liver to release glucose into the bloodstream, thus increasing blood sugar levels
What community members commonly report: Sustained energy improvements that persist after stopping injections Improved exercise tolerance and recovery Some report improved skin elasticity and reduced fine lines (subjective) Occasional reports of improved bloodwork markers (inflammatory markers, kidney function) Joint comfort improvements, particularly in those with pre-existing stiffness What to monitor: This is an appropriate time for follow-up bloodwork
Providers utilize SR9009 for patients struggling with profound lethargy, insulin resistance, and dyslipidemia, helping them improve endurance and mobilize stubborn fat stores
If the ECM has a high level of toxins, its health will be comprised